Can-Fite BioPharma, Namodenoson, Advanced Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, Phase IIa Trial, ESMO 2026, Clinical Trial, Oncology

RAMAT GAN, Israel — October 26, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF; TASE: CANF) announced final positive data...